A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Author:

Paul Barry1ORCID,Liedtke Michaela2ORCID,Khouri Jack3ORCID,Rifkin Robert4ORCID,Gandhi Mitul D5ORCID,Kin Andrew6,Levy Moshe Y7,Silbermann Rebecca8ORCID,Cottini Francesca9ORCID,Sborov Douglas W10ORCID,Sandhu Irwindeep11ORCID,Villarreal Lyssa12,Murphy Michael12ORCID,Gu Lin12ORCID,Chen Ann12,Rajakumaraswamy Nishanthan12ORCID,Usmani Saad Z13ORCID

Affiliation:

1. Levine Cancer Institute, Department of Hematologic Oncology and Blood Disorders, Charlotte, NC 28204, USA

2. Stanford Cancer Institute, Stanford Comprehensive Cancer Center, Stanford, CA 94305, USA

3. Taussig Cancer Institute, Cleveland Clinic, Department of Hematology and Medical Oncology, Cleveland, OH 44195, USA

4. Rocky Mountain Cancer Centers, US Oncology Research, Denver, CO 80218, USA

5. Virginia Cancer Specialists, Gainesville, VA 20155, USA

6. Barbara Ann Karmanos Cancer Institute, Wayne State University, Department of Oncology, Detroit, MI 48201, USA

7. Baylor University Medical Center, Department of Hematology and Medical Oncology, Dallas, TX 75246, USA

8. Oregon Health & Science University, Division of Hematology/Medical Oncology, Portland, OR 97239, USA

9. The Ohio State University Comprehensive Cancer Center, Department of Internal Medicine, Columbus, OH 43210, USA

10. Huntsman Cancer Institute, University of Utah, Department of Internal Medicine, Salt Lake City, UT 84112, USA

11. Cross Cancer Institute, University of Alberta, Department of Oncology, Edmonton, Alberta, T6G 1Z2, Canada

12. Gilead Sciences, Inc, Foster City, CA 94404, USA

13. Memorial Sloan Kettering Cancer Center, New York City, NY 10065, USA

Abstract

Magrolimab is a monoclonal antibody that blocks CD47, a ‘do not eat me’ signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies. These findings suggest that magrolimab-based combinations may have a therapeutic benefit in MM. This phase II study investigates magrolimab in combination with commonly used myeloma therapies in patients with relapsed/refractory MM and includes a safety run-in phase followed by a dose-expansion phase. Primary end points include the incidence of dose-limiting toxicities and adverse events (safety run-in) and the objective response rate (dose expansion).

Funder

Gilead Sciences

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3